A Study of IMC-1 In Patients With Fibromyalgia

Completed · Phase 2

Conditions studied: Fibromyalgia, Chronic Pain, Myofascial Pain

In brief

This is a randomized, double-blind, placebo-controlled, 16-week study designed to evaluate the hypothesis that tissue-resident herpes virus may be causally related to fibromyalgia symptoms or recurrence. IMC-1 is a combination treatment that is designed to suppress this suspected virus and thus alleviate fibromyalgia symptoms.

Key facts

Study ID

NCT01850420

Run by

Innovative Med Concepts, LLC

People needed

143

Starts

2013-05-01

Expected to finish

2014-03-01

Last updated by the study team

2015-03-27

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of fibromyalgia
• English speaker

You may not qualify if…

• Rheumatologic diseases
• Bipolar disease, OCD, severe anxiety, schizophrenia
• Systemic infection, severe cardiac disease, chronic steroid usage
• chronic opioid usage

Where it is running

• IMC Study Site — Birmingham, Alabama, United States
• IMC Study Site — Sacramento, California, United States
• IMC Study Site — San Diego, California, United States
• IMC Study Site — Vista, California, United States
• IMC Study Site — Jacksonville, Florida, United States
• IMC Study Site — Tampa, Florida, United States
• IMC Study Site — Evansville, Indiana, United States
• IMC Study Site — Lafayette, Indiana, United States
• IMC Study Site — Ann Arbor, Michigan, United States
• IMC Study Site — Raleigh, North Carolina, United States
• IMC Study Site — Medford, Oregon, United States
• IMC Study Site — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.